Company Description

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States.

Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.

The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Intensity Therapeutics, Inc.

Country	United States
Founded	2012
IPO Date	Jun 30, 2023
Industry	Biotechnology
Sector	Healthcare
Employees	7
CEO	Lewis Bender

Contact Details

Address: 1 Enterprise Drive, Suite 430 Shelton, Connecticut 06484-4779 United States
Phone	203 221 7381
Website	intensitytherapeutics.com

Stock Details

Ticker Symbol	INTS
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$5.00
CIK Code	1567264
CUSIP Number	45828J202
ISIN Number	US45828J2024
Employer ID	46-1488089
SIC Code	2836

Key Executives

Name	Position
Lewis H. Bender M.A., M.B.A., M.S.	Founder, President, Chief Executive Officer and Chairman of the Board
James M. Ahlers	Executive Vice President of Corporate Finance

Latest SEC Filings

Date	Type	Title
May 7, 2026	8-K	Current Report
May 7, 2026	10-Q	Quarterly Report
Apr 30, 2026	ARS	Filing
Apr 30, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 30, 2026	DEF 14A	Other definitive proxy statements
Mar 27, 2026	8-K	Current Report
Mar 27, 2026	10-K	Annual Report
Mar 23, 2026	8-K	Current Report
Mar 23, 2026	424B5	Filing
Mar 6, 2026	8-K	Current Report

View All SEC Filings